Remifemin Improve Gynecological Malignant Tumor Postoperative Patients Of Menopause Syndrome For The Clinical Research

Objective: Remifemin improve gynecological malignant tumor postoperative patients of menopause syndrome; The influence of bone metabolism; Evaluate the patients' estradiol, luteinizing hormone follicle stimulating hormone, lipids. Observation and drug related adverse reactions.Methods:Collect Dalian Maternity Hospitals from March 2010 to March 2011 by gynecologic malignant tumor resection of bilateral ovarian and preoperative not postmenopausal patients, 23 patients agree with Remifemin treatment postmenopausal symptoms. The patients between 43 to 54, 12 cases of endometrial carcinoma ,Ⅰperiod 8 cases,Ⅱperiod in 2 cases, 2 casesⅡperiod; Ovarian cancer in 5 patients, andⅠperiod 1 case ,in 2 casesⅡperiod ,2 casesⅡperiod; Cervical cancerⅠperiod in 2 cases, 2 cases (near menopause reason also removed the bilateral annex); borderline ovarian tumors in 2 casesⅠC period ,in 1 caseⅡperiod; 2 cases (postmastectomy breast surgeon suggest excision bilateral ovarian, change medications).Since the postoperatie patients with menopausal symptoms and improved Kupperman score》15 scores. Remifemin (an isopropanolic black cohosh extract) 40mg /d,treatment for 12 weeks. Improved kupperman score including hot perspire, insomnia, anxiety, depression, totaling 13 item, degree score of 0 ~ 3 points, weighted points: hot sweat is four points, cacesthesia,insomnia,anxiety,urinary tract symptoms,sex life weretwo points, the rest were for 1 minute. Weighted points for the multiply degree rating score, the total was the sum of the sum for each item. During the course of medication 0W 4W 8W and 12W by recording Kupperman score evaluatd its curative effect,( if improved Kupperman score < 15 points was effective), calculate the percentage of effective treatment for patients. For medication in 0W and12W detectd serum alkaline phosphatase, high-density lipoprotein cholesterol (hdl-c), low density lipoprotein, serum total cholesterol, serum triglyceride, estradiol, FSH, LH. Medication before and after detected blood routine and liver and kidney level, record patients experienced adverse reactions.Result:This experiment can be observed the Kupperman score dreased from21.70±5 to 8.65±4.97 after 12 weeks treatment, effective power was 85.7%.The hot sweat was reduced from 6.78±3.06 to 2.09±2.37 12 weeks treatment;Insomnia was reduced from4±1.6to 2.17±1.34after 12 weeks treatment;Anxiety depressed 6.13±1.84 to 3.39±1.16 after 12 weeks treatment; There were statistically significant differences(p < 0.05).E2 was 16.17±3.93pg/ml to 15.75±3.80 pg/ml after 12 weeks treatment;FSH was 65.23±16.24 mIU/ml to 66.14±17.29mIU/ml after 12 weeks treatment;LH was 39.12±10.24mIU/ml to 40.95±11.12mIU/ml after 12 weeks treatment, There were no statistically significant difference (p > 0.05). Serum alkaline phosphatase was ascended from 48±10.93IU/L to57±17.80IU/L, difference was statistically significant (p < 0.05). HDL-C was ascended from 1.37±0.35mmol/lto1.68±0.61mmol/l after 12 weeks treatment; LDL-C was ascended from 3.18±0.86mmol/l to 2.67±0.79mmol/l after 12 weeks treatment, difference was statistically significant (p < 0.05).TGL was from1.41±0.9mmol/lto 1.38±0.61mmol/lafter 12 weeks treatment ; CHOL from 5.27±0.9mmol/l to 5.23±0.83mmol/lafter 12 weeks treatment, there were no statistically significant difference (p > 0.05). Routine blood and blood biochemistry examines not happened clinically meaningful change, adverse effects weae 4 cases of gastrointestinal reaction.Conclusion: Remifemin was effective in relieving emotional symptoms,mainly hot flashes,insomnia and anxiety in patients,with no effect on E2,FSH,LH. Remifemin caused a slight but significant decrease of LDL-cholesterol,and increase of HDL-cholesterol, without affecting total cholesterol and triglycerdes. Fewer side effects, and light.